<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03428451</url>
  </required_header>
  <id_info>
    <org_study_id>N02112</org_study_id>
    <nct_id>NCT03428451</nct_id>
  </id_info>
  <brief_title>Prophylaxis Versus Treatment for TURP Syndrome.</brief_title>
  <official_title>Prophylaxis Versus Treatment Against TURP Syndrome : Role of Hypertonic Saline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmed Mohamed ELbadawy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the usage &amp; effects of prophylactic HS preloading, with
      two different concentrations, to combat the expected dilutional hyponatremia induced by
      irrigating fluid absorption and to prevent the occurrence of TURP syndrome with its potential
      complications
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted on 60 patients ASA class I - III BPH patients, candidates for
      TURP surgery using monopolar electronic resectoscope. Eligible patients will be allocated
      into one of three study groups (n=20 in each). Group A patients will receive NaCl 3% HS at a
      dose of 4 ml/kg/hr; Group B patients will receive NaCl 3% HS at a dose of 2 ml/kg/hr; while
      Group C patients will receive NaCl 0.9% Normal Saline(NS) at a dose of 6 ml/kg/hr. All
      intra-venous infusions will be started 30 minutes before the subarachnoid block, and
      continued all through the procedure at the same specific rate for each infusion. Vital signs
      [mean BP, HR, CVP &amp; oxygen saturation (spO2)] will be recorded. Plasma electrolytes (sodium,
      potassium, chloride)and serum osmolality (mOsm) will be measured. Incidence of TUR syndrome,
      need for ICU admission, post-operative ventilation and total hospital stay will be noted.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 10, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum sodium level measured in mEq/L</measure>
    <time_frame>72 hours</time_frame>
    <description>Hyponatremia was defined as a serum sodium &lt; 130 mEq/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of TURP syndrome</measure>
    <time_frame>72 hours</time_frame>
    <description>Occurring TURP syndrome manifestations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for ICU admission</measure>
    <time_frame>72 hours</time_frame>
    <description>For cardio-pulmonary support(vasopressor,mechanical ventilation), neurological monitoring</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Transurethral Resection of Prostate Syndrome</condition>
  <arm_group>
    <arm_group_label>Group A (Hypertonic saline )</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive NaCl 3% HS at a dose of 4 ml/kg/hr.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (Hypertonic saline)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive NaCl 3% HS at a dose of 2 ml/kg/hr.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (Normal saline)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive NaCl 0.9% NS at a dose of 6 ml/kg/hr.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 3% HS</intervention_name>
    <description>Hypertonic saline 3% is a type of crystalloid solution with osmolarity higher than that of plasma.</description>
    <arm_group_label>Group A (Hypertonic saline )</arm_group_label>
    <other_name>Hypertonic saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 3% HS</intervention_name>
    <description>Hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma.</description>
    <arm_group_label>Group B (Hypertonic saline)</arm_group_label>
    <other_name>Hypertonic saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0.9% NS</intervention_name>
    <description>Normal saline 0.9% is a type of crystalloid solution with osmolarity similar to that of plasma.</description>
    <arm_group_label>Group C (Normal saline)</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA class I - III BPH patients

        Exclusion Criteria:

          -  Patients having any condition contra-indicating regional anesthesia e.g impaired
             coagulation.

          -  Electrolyte imbalance,

          -  Uncontrolled hypertension,

          -  Congestive heart failure or being allergic to local anesthetics.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Adult male BPH patients</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed ELbadawy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of medicine- Cairo University- Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>January 26, 2018</study_first_submitted>
  <study_first_submitted_qc>February 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>December 23, 2018</last_update_submitted>
  <last_update_submitted_qc>December 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed ELbadawy</investigator_full_name>
    <investigator_title>Ahmed Mohamed ELbadawy- Clinical investigator , Cairo University</investigator_title>
  </responsible_party>
  <keyword>TURP</keyword>
  <keyword>hypertonic saline</keyword>
  <keyword>TURP syndrome</keyword>
  <keyword>hyponatraemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

